Celecoxib

Cat. No.: HY-14398
CAS No.: 169590-42-5
Molecular Formula: C₁₇H₁₄F₃N₃O₂S
Molecular Weight: 381.37
Target: COX
Pathway: Immunology/Inflammation
Storage:
- Powder: -20°C 3 years, 4°C 2 years, In solvent: -80°C 6 months, -20°C 1 month

Solvent & Solubility

**In Vitro**

DMSO: ≥ 50 mg/mL (131.11 mM)

* "≥" means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent</th>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1 mM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2.6221 mL</td>
<td>13.1106 mL</td>
<td>26.2213 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 mM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.5244 mL</td>
<td>2.6221 mL</td>
<td>5.2443 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.2622 mL</td>
<td>1.3111 mL</td>
<td>2.6221 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

**BIOLOGICAL ACTIVITY**

**Description**
Celecoxib is a selective COX-2 inhibitor with an IC₅₀ of 40 nM.

<table>
<thead>
<tr>
<th>IC₅₀ &amp; Target</th>
<th>COX-2</th>
<th>COX-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC₅₀</td>
<td>40 nM (IC₅₀)</td>
<td>15 μM (IC₅₀)</td>
</tr>
</tbody>
</table>
## In Vitro

The selective cyclooxygenase-2 (COX-2) inhibitor Celecoxib (10-75 μM) inhibits the proliferation of the NPC cell lines in a dose-dependent manner. Celecoxib (25 and 50 μM) induces apoptosis and cell-cycle arrest at the G0/G1 checkpoint in the NPC cell lines, which is associated with significantly reduced STAT3 phosphorylation. The genes downstream of STAT3 (ie, Survivin, Mcl-1, Bcl-2 and Cyclin D1) are significantly down-regulated after exposure to Celecoxib (25 and 50 μM).[2]

## In Vivo

Celecoxib demonstrates potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay with an ED50 of 7.1 mg/kg and reduces chronic inflammation in the adjuvant arthritis model with an ED50 of 34.5 mg/kg. Celecoxib has potency equivalent to that of standard nonsteroidal anti-inflammatory drugs (NSAIDs), yet shows no acute GI toxicity in rats at doses up to 200 mg/kg. In addition, it displays no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days.[1] In the KpB mice fed a high fat diet (obese) and treated with Celecoxib, tumor weight decreases by 66% when compared with control animals. Among KpB mice fed a low fat diet (non-obese), tumor weight decreases by 46% after treatment with Celecoxib.[3] Rat models are orally administered with Celecoxib (20 mg/kg) and/or intramuscularly with Fasudil (10 mg/kg) for 2 weeks. Results demonstrate that the combined use of Celecoxib and fasudil significantly decreases COX-2 and Rho kinase II expression surrounding the lesion site in rats with spinal cord injury, improves the pathomorphology of the injured spinal cord, and promoted the recovery of motor function[4].

## PROTOCOL

### Cell Assay[2]

The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 h. The cells are then treated with increasing concentrations of Celecoxib (0, 5, 10, 25, 50 or 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 h. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37°C for 4 h. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The percentage growth inhibition is calculated as (ODcontrol−ODdrug)/ODcontrol×100%. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration[3][4]

**Mice[3]**

The KpB mice are monitored weekly by palpation for tumor growth. Celecoxib and placebo treatment is initiated after palpation of a 1 cm tumor in mice on the HFD (obese group) and LFD (non-obese group) (N=15 mice per group). Celecoxib is dissolved in DMSO at 5 mg/mL, further diluted 10 times in 0.5% methylcellulose with 0.025% Tween 80 and injected (IP) daily at a dose of 5 mg/kg body weight for 4 weeks. The tumor sizes are measured once a week by palpation. Tumor volume is calculated using the following equation: volume (mm^3)=a×b^2/2, where a is the largest diameter and b is the smallest diameter. The animals are weighed weekly throughout the study. At sacrifice, mice are weighed and blood samples are taken. Half of the ovarian tumor is snap-frozen and stored at −80°C, and the other half is fixed in 10% neutral-buffered formalin and paraffin embedded. Mouse heart, lungs and kidneys are also harvested, fixed in formalin and grossly examined for any suspicious lesions before paraffin embedding.

**Rats[4]**

Forty adult, clean, female, Sprague-Dawley rats aged 3 months and weighing 280-330 g, are used. Forty rats are randomized to five groups as follows: sham surgery, model, Celecoxib, fasudil and combination groups, with eight rats in each group. Rats in the Celecoxib group are intragastrically administrated with a suspension of Celecoxib (20 mg/kg), and a suspension of Celecoxib containing 0.5% sodium carboxymethylcellulose is made from the capsules. Rats in the fasudil group are intramuscularly administrated with fasudil hydrochloride injection (10 mg/kg) via the dorsal muscle. Rats in the combination group are administrated with both a suspension of Celecoxib (20 mg/kg) and fasudil hydrochloride (10 mg/kg). The fasudil and Celecoxib doses are based on doses administered to adults and these are adjusted in a pre-study. Administration is once every day for 2 weeks. Subsequently, all rats are treated
normally for another 2 weeks, and then sacrificed either for histological examination or for western blot assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION


See more customer validations on www.MedChemExpress.com

REFERENCES


